Advanced Practice Providers

Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in cancer care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide. 

Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer. 

Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer. 

GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer

News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Articles

This and previous research from the Sethi Lab suggest Sox9 is a promising therapeutic target for colorectal cancer.

Sox9 protein enables molecular time travel that can lead to colorectal cancer

Physicians, clinicians and executive leaders of Florida Cancer Specialists & Research Institute, LLC (FCS) are joining industry experts from across the U.S. to envision the next 20 Years of Oncology Care.

Members from Florida Cancer Specialists & Research Institute Envision the Next 20 Years in Community Oncology Care

Every year, Huntsman Cancer Institute receives funding from the American Cancer Society to support the promising research of junior faculty. 

Five Researchers Awarded Pilot Project Funding

Rachel Ceballos, PhD, has been appointed senior director of community outreach and engagement at Huntsman Cancer Institute at the University of Utah .

Rachel Ceballos, PhD, Named Senior Director Of Community Outreach And Engagement 

Advocacy | Strategic Alliance Partners

Latest Conference Coverage